Table: monthly_update_prescription_drugs_intro_to_the_market_excel , manufacturer_name like A*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Accord BioPharma, Inc.	69448001505	Hercessi Intravenous Solution Reconstituted 150 MG	2025-01-03	1323.0000	None	1	42268	None	None	None	None	None	None	"There are challenges with estimating the number of patients due to Hercessi’s multiple indications approved by the FDA. Accord estimates patients using US Population and an annual U.S. incidence rate which results in 37,000 estimated patients for Breast Cancer and 4,800 estimated patients for Gastric Cancer. The US Population is from the Neilsburg Research US population by Gender, July 2024. This incidence rate is derived from the National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Female Breast Cancer. Available at: https://seer.cancer.gov/statfacts/html/breast.html. Accessed January 15, 2024"	None
Accord BioPharma, Inc.	69448001611	Hercessi Intravenous Solution Reconstituted 420 MG	2025-01-03	3704.4000	None	1	42268	None	None	None	None	None	None	"There are challenges with estimating the number of patients due to Hercessi’s multiple indications approved by the FDA. Accord estimates patients using US Population and an annual U.S. incidence rate which results in 37,000 estimated patients for Breast Cancer and 4,800 estimated patients for Gastric Cancer. The US Population is from the Neilsburg Research US population by Gender, July 2024. This incidence rate is derived from the National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Female Breast Cancer. Available at: https://seer.cancer.gov/statfacts/html/breast.html. Accessed January 15, 2024"	None
Akebia Therapeutics, Inc.	59922064160	VAFSEO TABLETS 1 PACK 60 TABS 150 MG	2025-01-09	1278.0000	The marketing plan for Vafseo is to highlight differentiation between Vafseo and the standard of care (including but not limited to its unique mechanism of action, stimulation of the body’s natural response to hypoxia, enhancing the body’s natural production of EPO, activating iron mobilization, controlling hemoglobin level over time, simple titration and few dose modifications, and convenient oral dosing). The Vafseo wholesale acquisition cost (WAC) for a 30-day supply at the labeled starting dose, considers various qualitative and quantitative factors, including but not limited to the cost of bringing the therapy to market, the impact of the CMS TDAPA payment for innovative therapies during and post- the TDAPA period on dialysis organizations, and the value of addressing critical patient needs.	None	500000	None	None	None	None	None	None	U.S. Dialysis Patients Treated for Anemia approximately 500,000 Patients. Akebia does not expect to capture 100% of the eligible treatable patients, but the exact share of patients that will be treated with Vafseo is unknowable at this time.	None
Akebia Therapeutics, Inc.	59922064260	VAFSEO TABLETS 1 PACK 60 TABS 300 MG	2025-01-09	2556.0000	The marketing plan for Vafseo is to highlight differentiation between Vafseo and the standard of care (including but not limited to its unique mechanism of action, stimulation of the body’s natural response to hypoxia, enhancing the body’s natural production of EPO, activating iron mobilization, controlling hemoglobin level over time, simple titration and few dose modifications, and convenient oral dosing). The Vafseo wholesale acquisition cost (WAC) for a 30-day supply at the labeled starting dose, considers various qualitative and quantitative factors, including but not limited to the cost of bringing the therapy to market, the impact of the CMS TDAPA payment for innovative therapies during and post- the TDAPA period on dialysis organizations, and the value of addressing critical patient needs.	None	500000	None	None	None	None	None	None	U.S. Dialysis Patients Treated for Anemia approximately 500,000 Patients. Akebia does not expect to capture 100% of the eligible treatable patients, but the exact share of patients that will be treated with Vafseo is unknowable at this time.	None
Amneal Pharmaceuticals	60219227902	Everolimus Tablets for Oral Suspension 2mg	2025-01-22	12894.9800	None	1	967	None	None	None	None	None	None	This product is being marketed in the generic, multisource space. This product was not acquired and was developed in house.	None
Amneal Pharmaceuticals	60219228002	Everolimus Tablets for Oral Suspension 3mg	2025-01-22	13024.1400	None	1	967	None	None	None	None	None	None	This product is being marketed in the generic, multisource space. This product was not acquired and was developed in house.	None
Amneal Pharmaceuticals	60219228102	Everolimus Tablets for Oral Suspension 5mg	2025-01-22	13555.5200	None	1	967	None	None	None	None	None	None	This product is being marketed in the generic, multisource space. This product was not acquired and was developed in house.	None
Amneal Pharmaceuticals	65162036018	Mesalamine Delayed-Release Tablets 800mg 180 ct	2025-02-19	1335.4500	None	1	32900	None	None	None	None	None	None	This product is being marketed in the generic, multisource space. This product was not acquired and was developed in house.	None
Amneal Pharmaceuticals	70121271502	Methylene Blue Injection, USP 50mg/10mL	2025-03-28	1980.0000	None	1	228000	None	None	None	None	None	None	This product is being marketed in the generic, multisource space. This product was not acquired and was developed in house.	None
ANIP	70954052210	INZIRQO - Powder, For Suspension - 10mg/ml - 80ml in 1 bottle	2025-03-10	375.0000	Promotion will consist of awareness campaigns to pharmacies via mail and email. In addition, there will be physician promotion to Pediatric Nephrology, Pediatric Cardiology and select Geriatric physicians.	None	9758721	None	None	None	None	None	None	None	None
Astellas Pharma US, Inc.	00469442530	VYLOY® (zolbetuximab - clzb) 300mg vial	2025-04-08	4800.0000	Astellas has not released the information requested (marketing/pricing plans) in the public domain. Further, Astellas does not believe this information is in the public domain or publicly available. As a result, Astellas is limiting its response to this reporting requirement pursuant to Cal. Health & Safety Code Section 127681(c).	None	6233	None	None	None	None	None	None	Astellas has not released the information requested in column 7 (estimated volume of patients that may be prescribed the drug) in the public domain. Further, Astellas does not believe this information is in the public domain or publicly available. As a result, Astellas is limiting its response to this reporting requirement pursuant to Cal. Health & Safety Code Section 127681(c).	None
Aurobindo Pharma USA, Inc.	59651058208	Pazopanib Tablets	2025-04-01	6500.0000	Generic drug market pricing	None	2200	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=1056, https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=1057
Aurobindo Pharma USA, Inc.	59651084918	Rivaroxaban 2.5mg tablets - 180s	2025-04-21	1435.3400	Generic drug, matched current generic approvals	None	30000	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=1058, https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=1059
AvKare	42291090328	Sunitinib Malate 37.5mg Capsule 28ct	2025-01-08	12089.0400	None	1	75000	None	None	None	None	None	None	While this drug was uploaded to the databanks back on 10/17/2023, this drug was not sold in the market until 01/08/2025. We were notified of this date of first sale in January 2025 and submitted the drug as soon as we were notified.	None
Avyxa Pharma, LLC	83831013101	AXTLE (pemetrexed) Injection 100 mg/vial, SDV	2025-01-01	790.0000	Please refer to the "CA_Marketing and Pricing Plan_AXTLE" document.	None	25000	None	None	2024-07-01	None	1	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=1054
Avyxa Pharma, LLC	83831013201	AXTLE (pemetrexed) Injection 500 mg/vial, SDV	2025-01-01	3950.0000	Please refer to the "CA_Marketing and Pricing Plan_AXTLE" document	None	21500	None	None	2024-07-01	None	1	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=1055